15862-34-7

Basic information

• Product Name: 5-Bromo-3-nitro-2-pyridinol
• Synonyms: BUTTPARK 43\57-80;5-BROMO-2-HYDROXY-3-NITROPYRIDINE;5-BROMO-3-NITRO-2-PYRIDINOL;5-BROMO-3-NITRO-2(1H)-PYRIDINONE;5-BROMO-3-NITROPYRIDIN-2-OL;5-bromo-3-nitro-2-pyridone;3-Bromo-6-hydroxy -5-nitropyridine;2-Hydroxy-5-Bromo-3-NitroPyridine
• CAS NO: 15862-34-7
• Molecular Formula: C₅H₃BrN₂O₃
• Molecular Weight: 218.99
• EINECS: 239-989-0
• Product Categories: blocks;Bromides;NitroCompounds;Pyridines;Pyridine;Pyridine series;Nucleotides and Nucleosides;Bromopyridines;Halopyridines;Bases & Related Reagents;Nucleotides
• Mol File: 15862-34-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 246-250 °C
• Boiling Point: 296.7 °C at 760 mmHg
• Flash Point: 133.2 °C
• Appearance: /
• Density: 1.98 g/cm³
• Vapor Pressure: 0.00141mmHg at 25°C
• Refractive Index: 1.647
• Storage Temp.: Refrigerator
• Solubility: DMSO, Methanol
• PKA: 6.31±0.10(Predicted)
• BRN: 383853
• CAS DataBase Reference: 5-Bromo-3-nitro-2-pyridinol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-3-nitro-2-pyridinol(15862-34-7)
• EPA Substance Registry System: 5-Bromo-3-nitro-2-pyridinol(15862-34-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-37/38-41-36/37/38-20
• Safety Statements: 26-36/37/39-36
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 15862-34-7(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

InChI:InChI=1/C5H3BrN2O3/c6-3-1-4(8(10)11)5(9)7-2-3/h1-2H,(H,7,9)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 6332-56-5 2-hydroxy-3-nitropyridine 
• 13466-38-1 5-bromopyridin-2-ol 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 

Downstream Products

• 98786-86-8 5-bromo-2-hydroxy-3-aminopyridine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 15862-37-0 2,5-dibromo-3-nitro-pyridine 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 796096-47-4 1-benzyl-5-bromo-3-nitro-1H-pyridin-2-one 
• 847777-33-7 5-bromo-3-nitropyridin-2-yl 4-methylbenzenesulfonate 
• 690265-69-1 5-(4-chloro-phenyl)-3-nitro-pyridin-2-ol 
• 153888-45-0 5-bromo-1-methyl-3-nitropyridine-2(1H)-one 
• 951123-01-6 2-benzyloxy-N-(2,5-dibromopyridin-3-yl)-acetamide 
• 1083326-05-9 N-(5-bromo-2-methoxy-pyridine-3-yl)cyclopropyl-sulfonamide 
• 910904-99-3 (E)-3-[3-(3-hydroxy-propyl)-2-phenethyl-3H-imidazo[4,5-b]pyridin-6-yl]-acrylic acid ethyl ester 
• 910904-96-0 3-(6-bromo-2-phenethyl-imidazo[4,5-b]pyridin-3-yl)-propan-1-ol 
• 869645-75-0 (S)-2-[5-Naphthalen-1-yl-2-oxo-3-(4-trifluoromethylbenzoylamino)-2H-pyridin-1-yl]-3-phenylpropionic acid methyl ester 
• 869645-74-9 (S)-2-[5-bromo-2-oxo-3-(4-trifluoromethylbenzoylamino)-2H-pyridin-1-yl]-3-phenylpropionic acid methyl ester 

Relevant articles and documents

DOCK1-INHIBITING COMPOUND AND USE THEREOF

Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably provided is a compound that has DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by the following formula (A) or a salt thereof: wherein X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group, or a hydrocarbon group; R1 and R2 are different, and each represents a hydrogen atom or a group represented by the following formula (A-1): (wherein R6 represents a pyrrolidino group or a phenyl group, and n2 is 0 or 1) ; R3 represents -CO-R7 (wherein R7 is an alkoxy group, an alkyl group, or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom, or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom, or a hydrocarbon group in which one or more hydrogen atoms may be replaced by one or more substituents; R5 represents a halogen atom, a halogenated alkyl group, or a halogenated alkylthio group; and n1 is an integer of 0 to 5; and

New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R9, X1 and X2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.